


Amendments to the Claims:






This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredients, an opioid analgesic and a therapeutically effective amount of a compound according to Formula (I)



the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and the prodrugs thereof, wherein

- n is 0, 1 or 2;
- m is 1 or 2, provided that if m is 2, then n is 1;
- p is 1 or 2;
- =Q is =O or =NR³;
- X is a covalent bond or a bivalent radical of formula -O-, -S-, -NR³-;
- R¹ is Ar¹, Ar¹C₁₋₆alkyl or di(Ar¹)C₁₋₆alkyl, wherein each C₁₋₆alkyl group is optionally substituted with hydroxy, C₁₋₄alkyloxy, oxo or a ketalized oxo substituent of formula -O-CH₂-CH₂-O- or -O-CH₂-CH₂-CH₂-O-;
- R² is Ar², Ar²C₁₋₆alkyl, Het¹ or Het¹C₁₋₆alkyl;
- R³ is hydrogen or C₁₋₆alkyl;
- L is hydrogen; Ar³; C₁₋₆alkyl; C₁₋₆alkyl substituted with 1 or 2 substituents selected from hydroxy, C₁₋₆alkyloxy, Ar³, Ar³C₁₋₆alkyloxy and Het²; C₃₋₆alkenyl; Ar³C₃₋₆alkenyl; di(Ar³)C₃₋₆alkenyl or a radical of formula



wherein

each q independently is 2, 3 or 4;

each r is 0, 1, 2, 3 or 4;

each Y¹ independently is a covalent bond, -O- or NR³;

Y² is a covalent bond, C₁₋₄alkanediyl or -C₁₋₄alkylNR³-;

each -A=B- independently is a bivalent radical of formula -CH=CH-, -N=CH- or -CH=N-;

each R⁴ independently is hydrogen, C₁₋₆alkyl, Ar² or Ar²C₁₋₆alkyl;

R⁵ is hydrogen, C₁₋₆alkyl or Ar³;

R⁶ is C₁₋₆alkyl, Ar³, Ar³C₁₋₆alkyl, di(Ar³)C₁₋₆alkyl, Ar³C₃₋₇cycloalkyl, or indolyl;

R⁷ is Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; C₁₋₆alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl substituted with Ar³; oxazolyl; oxazolyl substituted with halo or C₁₋₆alkyl; thiazolyl; thiazolyl substituted with halo or C₁₋₆alkyl; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl, Ar³C₁₋₆alkyl or halo; indolyl; indolyl substituted with C₁₋₄alkyl; 2,3,4-trihydroquinolyl; pyrrolidinyl or furanyl;

each R ⁸	independently is hydrogen, C ₁₋₆ alkyl, C ₃₋₇ cycloalkyl or a radical of formula of formula -Alk-R ¹¹ (b-1) or -Alk-Z-R ¹² (b-2);
wherein	
Alk	is C ₁₋₆ alkanediyl;
Z	is a bivalent radical of formula -O-, -S- or -NR ³ -;
R ¹¹	is phenyl; phenyl substituted with 1 or 2 substituents selected from halo, C ₁₋₆ alkyl or C ₁₋₆ alkyloxy; furanyl; furanyl substituted with 1 or 2 substituents selected from C ₁₋₆ alkyl or hydroxyC ₁₋₆ alkyl; thienyl; thienyl substituted with 1 or 2 substituents selected from halo or C ₁₋₆ alkyl; oxazolyl; oxazolyl substituted with 1 or 2 C ₁₋₆ alkyl substituents; thiazolyl; thiazolyl substituted with 1 or 2 C ₁₋₆ alkyl substituents; pyridinyl or pyridinyl substituted with 1 or 2 C ₁₋₆ alkyl substituents;
R ¹²	is C ₁₋₆ alkyl or C ₁₋₆ alkyl substituted with hydroxy, carboxyl or C ₁₋₆ alkyloxy; carbonyl;
Ar ¹	is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C ₁₋₄ alkyl, haloC ₁₋₄ alkyl, cyano, aminocarbonyl, C ₁₋₄ alkyloxy and haloC ₁₋₄ alkyloxy;
Ar ²	is naphthalenyl; phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of hydroxy, halo, cyano, nitro, amino, mono- or di(C ₁₋₄ alkyl)amino, C ₁₋₄ alkyl, haloC ₁₋₄ alkyl, C ₁₋₄ alkyloxy, haloC ₁₋₄ alkyloxy, carboxyl, C ₁₋₄ alkyloxy; carbonyl, aminocarbonyl and mono- and di(C ₁₋₄ alkyl)aminocarbonyl;
Ar ³	is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from the group consisting of halo, hydroxy, amino, nitro, aminocarbonyl, C ₁₋₆ alkyl, haloC ₁₋₆ alkyl and C ₁₋₆ alkyloxy;
Het ¹	is a monocyclic heterocycle selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group consisting of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl; each monocyclic and bicyclic heterocycle may optionally be

- Het² substituted on a carbon atom by 1 or 2 substituents selected from the group consisting of halo, C₁₋₄alkyl or mono-, di- and tri(halo)methyl; and is a heterocycle selected from the group consisting of 1,4-dihydro-5-oxo-tetrazol-1-yl, imidazo[1,2-a]pyridinyl, oxazolyl and imidazolyl; each of said heterocycles may be substituted with 1 or where possible 2 substituents selected from the group consisting of C₁₋₄alkyl and Ar³.
2. (Previously Amended) A pharmaceutical composition according to claim 1 wherein,
- L is hydrogen; C₁₋₆alkyl; C₁₋₆alkyl substituted with hydroxy; C₃₋₆alkenyl; Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; Ar³C₃₋₆alkenyl; di(Ar³)C₁₋₆alkenyl; or a radical of formula (a-1), (a-2), (a-4) or (a-5) wherein :
- R⁷ is Ar³; Ar³C₁₋₆alkyl; di(Ar³)C₁₋₆alkyl; C₁₋₆alkyl; C₃₋₇cycloalkyl; C₃₋₇cycloalkyl substituted with Ar³; oxazolyl; oxazolyl substituted with halo or C₁₋₆alkyl; thiazolyl; thiazolyl substituted with halo or C₁₋₆alkyl; imidazolyl; imidazolyl substituted with Ar³, C₁₋₆alkyl, Ar³C₁₋₆alkyl or halo; pyrrolidinyl or furanyl;
- Ar³ is phenyl or phenyl substituted with 1, 2 or 3 substituents selected from halo, hydroxy, amino, aminocarbonyl, C₁₋₆alkyl, haloC₁₋₆alkyl or C₁₋₆alkyloxy;
- Het¹ is a monocyclic heterocycle selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocycle selected from the group consisting of quinolinyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothieryl; each monocyclic and bicyclic heterocycle may optionally be substituted on a carbon atom by 1 or 2 substituents selected from the group consisting of halo, C₁₋₄alkyl or mono-, di- and tri(halo)methyl.
3. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, R¹ is Ar¹methyl and attached to the 2-position or R¹ is Ar¹ and attached to the 3-position.
4. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, R²-X-C(=Q)- moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.

5. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, R^1 is $Ar^1C_{1-6}alkyl$, R^2 is phenyl substituted with 2 substituents selected from the group consisting of methyl and trifluoromethyl, X is a covalent bond and $=Q$ is $=O$.
6. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, n and m are 1 and p is 1 or 2.
7. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, R^1 is phenylmethyl; R^2 is phenyl substituted with 2 substituents selected from the group consisting of methyl and trifluoromethyl; n, m and p are 1; X is a covalent bond; and $=Q$ is $=O$.
8. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, L is a radical of formula (a-2) wherein R^4 is hydrogen or phenyl; r is 0 or 1; Y^1 is a covalent bond, -O- or -NH-; R^7 is pyrrolidinyl; furanyl; 1-phenylcyclohexanyl; diphenylmethyl; or phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of methyl, methoxy and chloro
9. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises a compound selected from the group consisting of :
 - o 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide;
 - o 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(1-phenylcyclohexyl)-1-piperazine acetamide;
 - o 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-[4-[(1-pyrrolidinylcarbonyl)benzyl]-1-piperazinyl]piperidine;
 - o 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[(2-methyl-5-oxazolyl)methyl]-1H-benzimidazol-2-yl]-1-piperazinyl]-2-(phenylmethyl)piperidine;
 - o 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-trifluoromethylphenyl)methyl]-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide; and
 - o 4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(3,4-dichlorophenyl)methyl]-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-piperazine acetamide.

10. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition comprises a compound selected from the group consisting of :
 - (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide;
 - (-)-(B)-*cis*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide; and
 - (+)-(B)-*trans*-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-*N*-(2,6-dimethylphenyl)-1-piperazine acetamide (L)-malic acid (1:1).
11. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the pharmaceutical composition is formulated for simultaneous, separate or sequential use.
12. (Previously Amended) A pharmaceutical composition according to claim 1 wherein, the opioid analgesic is one or more compounds selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanyl, codeine, diacetylmorphine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levorphanol, lofentanyl, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanyl and sufentanyl; and derivatives and pharmaceutical acceptable salts thereof.
13. (Previously Amended) A pharmaceutical composition according to claim 12 wherein the opioid analgesic is one or more compounds selected from the group consisting of oxycodone, codeine, morphine, fentanyl, buprenorphine, hydrocodone, hydromorphone and pharmaceutical acceptable salts and derivatives thereof.
14. (Previously Amended) A pharmaceutical composition according to claim 1 where, the pharmaceutical composition is in a form suitable to be orally administered.
15. (Canceled) The use of a pharmaceutical composition according to claim 1, for the prevention and/or treatment of pain and/or nociception.
16. (Canceled) The use of a pharmaceutical composition according to claim 1, for the

prevention and/or treatment of acute and chronic pain, more in particular in inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain treatments.

17. (Canceled) The use of a pharmaceutical composition according to claim 1, for the prevention and/or treatment of emesis in opioid-based treatments of pain.
18. (Canceled) The use of a pharmaceutical composition according to claim 17 for the prevention and/or treatment of nausea and vomiting in opioid-based treatments of pain.
19. (Canceled) The use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for the prevention and/or treatment of respiratory depression in opioid-based treatments of pain.
20. (Canceled) The use of an NK₁-receptor antagonist, in particular an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof, for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain.
21. (New) A method for treating pain and/or nociception comprising administering to a person in need thereof an effective amount of a pharmaceutical composition according to claim 1.
22. (New) A method for treating acute and chronic pain selected from the group consisting of inflammatory, post-operative, emergency room (ER), breakthrough, neuropathic and cancer pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.
23. (New) A method for treating emesis in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 1.

24. (New) A method for treating nausea and vomiting in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of a pharmaceutical composition according to claim 23.
25. (New) A method for treating respiratory depression in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK₁-receptor antagonist selected from an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.
26. (New) A method for reducing and/or overcoming the tolerance observed with opioids in opioid-based treatments of pain comprising administering to one in need thereof an effective amount of an NK₁-receptor antagonist selected from the group consisting of an NK₁-receptor antagonist according to Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the *N*-oxide form thereof and prodrugs thereof.